Atlanta, Georgia · Biopharma Intelligence · Doctoral Research · Ventures · Mentoring

I help people make hard decisions with better evidence.

I'm Puru Gaur: a Director of Competitive Intelligence at a leading life sciences advisory firm, a Doctor of Business Administration in Health candidate at University College London — ranked #9 in the world in the QS World University Rankings 2026 — and the builder of a family of practical ventures. This site is my hub: the work, the research, the ventures, and the mentoring.

  • 10 years in biopharma and health policy
  • Emory MPH
  • Arizona MBA
  • Doctor of Business Administration in Health candidate, University College London (#9 in the world)
  • A family of ventures
  • Volunteer instructor and mentor since 2015
The Signal Map

The Capability Ledger

Five things I do, what each one means in plain English, and where to go next. Start anywhere.

The Person

Meet Puru Gaur.

Portrait of Puru Gaur with the Atlanta skyline behind him
Puru Gaur · Atlanta, Georgia

I'm an Atlanta-based biopharma intelligence leader. I turn deals, data, and regulatory chess moves into decisions people can act on.

My career spans Biogen, PhRMA, AmerisourceBergen (now Cencora), EVERSANA, and Vir Biotechnology. Today, I'm a Director of Competitive Intelligence at a leading life sciences advisory firm, where I advise clients across the spectrum — from multi-billion-dollar pharmaceutical companies to smaller biotechs.

I hold an MPH in Health Policy and Management from Emory University, home of the Rollins School of Public Health, ranked #2 in the nation by U.S. News & World Report, and an MBA in Healthcare Management from the University of Arizona, ranked #7 in the nation by U.S. News & World Report. I'm now a Doctor of Business Administration in Health candidate at the Global Business School for Health, University College London — ranked #9 in the world in the QS World University Rankings 2026.

My doctoral research asks a practical question: how do health systems pay for one-time curative therapies when the payment system was built for chronic care? I'm studying outcomes-based financing — spreading the cost over time and tying payment to whether the therapy delivers the result it promises — beginning with advanced therapies for vision restoration. One of my starting points is the 2008 mortgage crisis — a floor, not a ceiling, for how pooled financing should be built. Read the research →

Beyond the desk, I volunteer as a Taekwondo instructor for children in under-resourced neighbourhoods and serve as a public-health advisor with Ladybug for Girls®. Ladybug for Girls® Sport Wellness is an American sports-based youth development program that provides girls ages 5-12 years with evidence-based health education classes and sport safety resources. The principle is simple: plant trees under whose shade you do not expect to sit.

Based inAtlanta, Georgia
Experience10 years across biopharma and health policy
EducationEmory MPH · University of Arizona MBA
Doctoral researchFinancing curative therapies — University College London
VenturesFounder of a family of practical ventures
ServiceVolunteer instructor and mentor since 2015
Read the full bio → View résumé →
Doctoral Research

Paying for cures, honestly.

A one-time cell or gene therapy can deliver decades of benefit, but the bill arrives on day one — and the savings land with everyone except the payer who wrote the cheque: patients, families, employers, and public programs. My doctoral research at University College London — ranked #9 in the world — asks how health systems close that gap.

My starting point is the 2008 mortgage crisis. Structured finance didn't fail because pooling risk is a bad idea; it failed on misaligned incentives, weak underwriting, mispriced risk, and pools nobody could see inside. Treat 2008 as the floor, not the ceiling — the minimum lessons a new structure has to beat, not the limit of what's possible.

So the work tests a structure built to beat that floor: payments tied to independently verified outcomes, risk pooled honestly across patients and payers, transparent terms, and stress tests for the bad years — starting with therapies that restore vision, where the return shows up as independence and work, not just sight.

Read the research →
Beyond the Desk

Quality control has paws.

Momo, a Golden Retriever, brings the enthusiasm. Leo, a German Shepherd, brings the standards. Together they review the household's important decisions daily — walks, snacks, and whether a plan is actually ready.

Meet Momo & Leo →
Momo, a Golden Retriever
Momo · Chief Enthusiasm Officer
Leo, a German Shepherd
Leo · Head of Standards
How I Work

The Transparency Promise

The ventures change. The operating standard doesn't.

  1. 01
    Decisions run through a person

    Every decision runs through Puru — nothing ships on autopilot.

  2. 02
    Published work is verified

    Anything AI-assisted is checked by a human before it reaches you.

  3. 03
    Claims stay honest

    No fake reviews, no invented results, and no borrowed credibility.

  4. 04
    Sources stay public

    Public claims link to public sources, so you can check the work.

  5. 05
    Mistakes get corrected

    If something is wrong, it gets corrected publicly.

Working on a hard decision? Let's talk.

Contact Puru →